In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

Investigators sought to determine the cost-effectiveness of home- versus clinic-based anal cancer screening for increasing uptake among sexual and gender minorities.

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Dr Andrew Howard, chairman and president of the Kidney Transplant Collaborative, told the Associated Press that the drop off in kidney transplants would have been larger if not for a small increase of ...

Investigators sought to describe the patterns of post-progression outcome for patients with HR+/HER2- advanced breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Researchers investigated whether the time interval between a positive FIT result and follow-up colonoscopy is linked to risk for CRC.

Investigators evaluated the association between risk-reducing bilateral mastectomy and overall and breast cancer–specific mortality in female carriers of BRCA pathogenic variants.

Investigators assessed the association between race, ethnicity and neighborhood-level SES with mortality among young adults with mCRC.

Adding elraglusib to chemotherapy significantly increases overall survival in patients with previously untreated metastatic PDAC.

The use of GLP-1 receptor antagonist therapy has led to a greater reduction in colorectal cancer incidence than has been observed with aspirin.

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.